Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMX-150 for Pain in Diabetic Peripheral Neuropathy
NCT00641953Phase 2Completed
- Sponsor
- Procris Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IMX-150 in diabetic peripheral neuropathy (DPN) (3 arms), sponsored by Procris Pharmaceuticals. Primary endpoint: Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain '24 - Hour Average Pain' scores. Started Aug 2007; status: completed.
02
Drugs
IMX-150
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT00641953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641953.